BiTrial CRO | Serbia
Serbia is a vibrant country in Southeast Europe, known for its rich history, diverse culture, and stunning landscapes. Though not an EU member, Serbia is actively working toward membership and modernizing its economic and energy sectors.
Non EU member state; Partnership with United States, preferential trade regime with the EU and EMA and free trade agreements with CEFTA and EFTA
Total population: 6.641.964* (2026)
Conducting clinical trials in Serbia offers access to a diverse patient population and high-quality healthcare infrastructure, ensuring robust and generalizable study results. The country’s experienced medical professionals and advanced research facilities meet international standards. Serbia also has a supportive regulatory environment with streamlined approval processes, facilitating efficient trial management. Additionally, lower operational costs make it a cost-effective option compared to Western Europe or the U.S. High patient adherence and retention further enhance the reliability of trial outcomes.
🏥 Is Serbia a good country for clinical research?
Strategic location with strong partnerships with the United States and preferential agreements with the EU, EMA, CEFTA, and EFTA.
⏱️ How is the regulatory environment for clinical trials in Serbia?
Enhanced regulatory framework with validated safety guidelines overseen by the Medical Devices Agency.
🤝 Why is patient recruitment effective in Serbia?
High recruitment rates supported by a diverse patient population.
👨⚕️ Are clinical research teams in Serbia reliable?
Well-educated, highly trained workforce ensuring adherence to global clinical research standards.
🏥 What is the quality of clinical research in Serbia?
Rapidly growing sector committed to maintaining high-quality standards.